Have any questions? 706-721-6582 or cts@augusta.edu
- 4020-01-001: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (AMBER)
Clinical Trial
4020-01-001: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (AMBER)
This study is being done to learn more about TSR-022 and its effect on cancer when used either alone or in combination with one other investigational drug called Dostarlimab (TSR-042). TSR-022 given alone or in combination with TSR-042 is considered investigational. This study is divided into 2 parts; participants are being asked to participate in Part 2 cohort D of this study. Part 2 cohort D will enroll patients with advanced non-small cell lung cancer (NSCLC) who have received a specific type of prior cancer treatment and have a certain expression of a tumor marker as determined by testing biopsy tissue.
Eligibility Criteria
- Male or female, aged 18 years or older Patients with advanced or metastatic Non-Small Cell Lung Cancer that is measurable by CT or MRI
RESEARCH. INNOVATION. DISCOVERY.